As powerful new weight loss injections like retatrutide make headlines, more people are asking whether rapid fat loss could come with an unexpected cost: thinning hair, shedding, or patchy bald spots
How Are They Different From Each Other
Widespread use of the drugs allows a broader and deeper look at what this class can do both benefits and risks
These peptides are unapproved bulk drug substances with no approved indication for any of them
Epidemiology Gamma-glutamylcysteine synthetase deficiency is very rare disease
Dec 18, 2025, 08:00 ET CagriSema 2.4 mg/2.4 mg is an investigational fixed-dose injectable medicine that combines the novel amylin analogue, cagrilintide, with semaglutide to target complementary obesity-related pathways 1,2 In the REDEFINE 1 phase 3 trial, adults with obesity, or overweight with at least one obesity-related complication, taking CagriSema lost an average of 23% body weight when evaluating the treatment effect if all patients stayed on treatment *2 Novo Nordisk continues to build on its 100-year-plus legacy of science and innovation, with potential new treatments in obesity PLAINSBORO, N.J
